Ras association domain family member 8Genealiases: C12orf2 · HOJ1
Q-omics provides the consensus-scored RASSF8 profile across patient tissues and cancer cell-line models. RASSF8 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, RASSF8 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RASSF8 protein abundance shows 35,865 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, KIRC, and GBM as cancer lineages where RASSF8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASSF8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASSF8 survival associations across molecular data types. RASSF8 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASSF8 RNA expression–survival associations across cancer types. High RASSF8 expression shows unfavorable associations in LGG, STAD and LUSC, but favorable associations in KIRC, BRCA and MESO. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for RASSF8 RNA expression.
This table summarizes RASSF8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RASSF8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASSF8 shows lower tumor expression in KIRC, LUAD, THCA, KICH and LUSC and higher tumor expression in HNSC. The KIRC box plot shows higher RASSF8 RNA expression in normal versus tumor tissue (log2 FC = −1.153, t-test p < 0.001).
This table shows molecular features associated with RASSF8 in patient tissues and cancer cell lines. In patient samples, RASSF8 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RASSF8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
